Weber JS - Search Results

1

T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study.

Gainor JF, Patel MR, Weber JS, Gutierrez M, Bauman JE, Clarke JM, Julian R, Scott AJ, Geiger JL, Kirtane K, Robert-Tissot C, Coder B, Tasneem M, Sun J, Zheng W, Gerbereux L, Laino A, Porichis F, Pollard JR, Hou P, Sehgal V, Chen X, Morrissey M, Daghestani HN, Feldman I, Srinivasan L, Frederick JP, Brown M, Aanur P, Meehan R, Burris HA 3rd. Gainor JF, et al. Among authors: weber js. Cancer Discov. 2024 Nov 1;14(11):2209-2223. doi: 10.1158/2159-8290.CD-24-0158. Cancer Discov. 2024. PMID: 39115419 Clinical Trial.

2

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA 3rd, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J. Flaherty KT, et al. N Engl J Med. 2012 Nov 1;367(18):1694-703. doi: 10.1056/NEJMoa1210093. Epub 2012 Sep 29. N Engl J Med. 2012. PMID: 23020132 Free PMC article. Clinical Trial.

3

Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T Cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma.

Woods DM, Ramakrishnan R, Laino AS, Berglund A, Walton K, Betts BC, Weber JS. Woods DM, et al. Among authors: weber js. Clin Cancer Res. 2018 Dec 15;24(24):6236-6247. doi: 10.1158/1078-0432.CCR-18-1100. Epub 2018 Aug 21. Clin Cancer Res. 2018. PMID: 30131384 Free PMC article.

4

HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics.

Laino AS, Betts BC, Veerapathran A, Dolgalev I, Sarnaik A, Quayle SN, Jones SS, Weber JS, Woods DM. Laino AS, et al. Among authors: weber js. J Immunother Cancer. 2019 Feb 6;7(1):33. doi: 10.1186/s40425-019-0517-0. J Immunother Cancer. 2019. PMID: 30728070 Free PMC article.

5

Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells.

Ichikawa J, Yoshida T, Isser A, Laino AS, Vassallo M, Woods D, Kim S, Oelke M, Jones K, Schneck JP, Weber JS. Ichikawa J, et al. Among authors: weber js. Clin Cancer Res. 2020 Jul 1;26(13):3384-3396. doi: 10.1158/1078-0432.CCR-19-3487. Epub 2020 Apr 2. Clin Cancer Res. 2020. PMID: 32241816 Free PMC article.

6

C reactive protein impairs adaptive immunity in immune cells of patients with melanoma.

Yoshida T, Ichikawa J, Giuroiu I, Laino AS, Hao Y, Krogsgaard M, Vassallo M, Woods DM, Stephen Hodi F, Weber J. Yoshida T, et al. J Immunother Cancer. 2020 Apr;8(1):e000234. doi: 10.1136/jitc-2019-000234. J Immunother Cancer. 2020. PMID: 32303612 Free PMC article.

7

Nivolumab and ipilimumab are associated with distinct immune landscape changes and response-associated immunophenotypes.

Woods DM, Laino AS, Winters A, Alexandre J, Freeman D, Rao V, Adavani SS, Weber JS, Chattopadhyay PK. Woods DM, et al. Among authors: weber js. JCI Insight. 2020 Jun 4;5(11):e137066. doi: 10.1172/jci.insight.137066. JCI Insight. 2020. PMID: 32369447 Free PMC article. Clinical Trial.

8

Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition.

Laino AS, Woods D, Vassallo M, Qian X, Tang H, Wind-Rotolo M, Weber J. Laino AS, et al. J Immunother Cancer. 2020 Jun;8(1):e000842. doi: 10.1136/jitc-2020-000842. Epub 2020 Jun 23. J Immunother Cancer. 2020. PMID: 32581042 Free PMC article.

9

Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma.

Weber JS, Levinson BA, Laino AS, Pavlick AC, Woods DM. Weber JS, et al. Melanoma Res. 2022 Oct 1;32(5):324-333. doi: 10.1097/CMR.0000000000000818. Epub 2022 Jun 9. Melanoma Res. 2022. PMID: 35678233 Free PMC article. Clinical Trial.

10

Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.

Weber JS, Zarour H, Redman B, Trefzer U, O'Day S, van den Eertwegh AJ, Marshall E, Wagner S. Weber JS, et al. Cancer. 2009 Sep 1;115(17):3944-54. doi: 10.1002/cncr.24473. Cancer. 2009. PMID: 19536884 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

267 results

Search Page

Filters